Category

Archives

TAM Receptor

Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma

18 views | Jun 11 2020

Michaël H Meel et al. found that combined inhibition of AXL and HDACs in DIPG cells results in a synergistic antitumor effect by reversing their mesenchymal, stem cell-like, therapy-resistant phenotype. [Read the Full Post]

AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells

17 views | Jun 11 2020

Olivier Zajac et al. demonstrated that AXL controls directed cell migration most likely by regulating cell polarity. [Read the Full Post]

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia

0 views | May 25 2020

Isabel Ben-Batalla et al. showed that Axl inhibition had therapeutic potential in BCR-ABL TKI-sensitive as well as resistant CML and support the need for clinical trials. [Read the Full Post]

Axl Inhibitor R428 Induces Apoptosis of Cancer Cells by Blocking Lysosomal Acidification and Recycling Independent of Axl Inhibition

25 views | May 25 2020

Fangfang Chen et al. uncovered a novel function and mechanism of R428 in addition to its ability to inhibit Axl. [Read the Full Post]

Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)

101 views | Dec 27 2019

Yang PW et al. revealed the great potential of using cabozantinib for targeted therapy of ESCC. [Read the Full Post]

Growth Arrest Specific Protein (Gas)-6/AXL Signaling Induces Preeclampsia (PE) in Rats

114 views | Nov 16 2019

Hirschi KM et al.provided insight into pathways associated with PE that could be useful in the clarification of potential therapeutic approaches. [Read the Full Post]

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia

127 views | Sep 14 2019

Erdmann R et al. showed that Axl inhibition has therapeutic potential in BCR-ABL TKI-sensitive as well as -resistant CML and support the need for clinical trials. [Read the Full Post]

ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial

482 views | Jun 02 2019

Gorcea CM et al. showed that ASP2215 (gilteritinib) is a novel, dual FLT3/AXL inhibitor with promising early phase trial data (NCT02014558). [Read the Full Post]

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

167 views | Apr 24 2019

Pinato DJ et al. found that suppression of Axl-dependent signalling influences the transformed phenotype in HCC cells and contributes to adaptive resistance to sorafenib, providing a pre-clinical rationale for the development of Axl inhibitors as a measure to overcome sorafenib resistance. [Read the Full Post]

Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout

279 views | Nov 09 2018

Liu L et al. revealed that IL-37 limits runaway inflammation initiated by MSU crystal-induced immune responses, partly in a Mertk-dependent fashion. Thus, rhIL-37 has both preventive and therapeutic effects in gouty arthritis. [Read the Full Post]